Invivo Therapeutics Holdings Corp Company Profile (OTCMKTS:NVIV)

About Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)

Invivo Therapeutics Holdings Corp logoInVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:NVIV
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: $65.92 million
  • Outstanding Shares: 32,154,000
Average Prices:
  • 50 Day Moving Avg: $3.42
  • 200 Day Moving Avg: $4.20
  • 52 Week Range: $2.00 - $7.94
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.66
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.75 per share
  • Price / Book: 2.73
Profitability:
  • EBIDTA: ($24,620,000.00)
Misc:
  • Average Volume: 248,302 shs.
  • Short Ratio: 14.02
 

Frequently Asked Questions for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)

What is Invivo Therapeutics Holdings Corp's stock symbol?

Invivo Therapeutics Holdings Corp trades on the OTCMKTS under the ticker symbol "NVIV."

How were Invivo Therapeutics Holdings Corp's earnings last quarter?

Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) issued its quarterly earnings results on Friday, November, 4th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.02. During the same period in the previous year, the business posted ($0.22) EPS. View Invivo Therapeutics Holdings Corp's Earnings History.

Where is Invivo Therapeutics Holdings Corp's stock going? Where will Invivo Therapeutics Holdings Corp's stock price be in 2017?

2 brokers have issued 1-year target prices for Invivo Therapeutics Holdings Corp's stock. Their predictions range from $6.00 to $23.25. On average, they anticipate Invivo Therapeutics Holdings Corp's stock price to reach $14.63 in the next year. View Analyst Ratings for Invivo Therapeutics Holdings Corp.

Who are some of Invivo Therapeutics Holdings Corp's key competitors?

How do I buy Invivo Therapeutics Holdings Corp stock?

Shares of Invivo Therapeutics Holdings Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Invivo Therapeutics Holdings Corp stock cost?

One share of Invivo Therapeutics Holdings Corp stock can currently be purchased for approximately $2.05.

Analyst Ratings

Consensus Ratings for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.63

Analysts' Ratings History for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Show:
DateFirmActionRatingPrice TargetDetails
5/5/2017Raymond James Financial, Inc.Reiterated RatingStrong-Buy -> Outperform$10.00 -> $6.00View Rating Details
7/21/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$23.25View Rating Details
5/12/2016HC WainwrightReiterated RatingBuyView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Earnings by Quarter for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Earnings History by Quarter for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/4/2016Q3($0.20)($0.18)ViewN/AView Earnings Details
8/4/2016Q2($0.22)($0.18)ViewN/AView Earnings Details
5/6/2016Q1 2016($0.26)($0.20)ViewN/AView Earnings Details
11/4/2015Q3 2015($0.20)($0.22)ViewN/AView Earnings Details
8/5/2015Q2 2015($0.18)($0.21)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.11)($0.22)ViewN/AView Earnings Details
3/17/2014($0.08)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Current Year EPS Consensus Estimate: $-0.75 EPS
Next Year EPS Consensus Estimate: $-0.77 EPS

Dividends

Dividend History for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Insider Trades by Quarter for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Insider Trades by Quarter for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/9/2014Francis ReynoldsMajor ShareholderSell50,000$1.20$60,000.00View SEC Filing  
5/5/2014Francis ReynoldsMajor ShareholderSell37,500$1.87$70,125.00View SEC Filing  
4/30/2014Francis ReynoldsMajor ShareholderSell37,500$1.82$68,250.00View SEC Filing  
4/25/2014Francis ReynoldsMajor ShareholderSell50,000$1.52$76,000.00View SEC Filing  
4/21/2014Francis ReynoldsMajor ShareholderSell50,000$1.57$78,500.00View SEC Filing  
4/14/2014Francis ReynoldsMajor ShareholderSell37,500$1.63$61,125.00View SEC Filing  
4/9/2014Francis ReynoldsMajor ShareholderSell37,500$1.60$60,000.00View SEC Filing  
4/4/2014Francis ReynoldsMajor ShareholderSell25,000$1.71$42,750.00View SEC Filing  
4/2/2014Francis ReynoldsMajor ShareholderSell37,500$1.71$64,125.00View SEC Filing  
3/26/2014Francis ReynoldsMajor ShareholderSell47,900$1.80$86,220.00View SEC Filing  
3/21/2014Francis ReynoldsMajor ShareholderSell39,600$2.15$85,140.00View SEC Filing  
3/17/2014Francis ReynoldsMajor ShareholderSell37,500$2.44$91,500.00View SEC Filing  
3/12/2014Francis ReynoldsMajor ShareholderSell37,500$2.33$87,375.00View SEC Filing  
3/7/2014Francis ReynoldsMajor ShareholderSell25,000$2.44$61,000.00View SEC Filing  
3/5/2014Francis ReynoldsMajor ShareholderSell37,500$2.49$93,375.00View SEC Filing  
2/28/2014Francis ReynoldsMajor ShareholderSell25,000$2.44$61,000.00View SEC Filing  
2/26/2014Francis ReynoldsMajor ShareholderSell37,500$2.28$85,500.00View SEC Filing  
2/21/2014Francis ReynoldsMajor ShareholderSell25,000$2.23$55,750.00View SEC Filing  
2/19/2014Francis ReynoldsMajor ShareholderSell25,000$2.25$56,250.00View SEC Filing  
2/14/2014Francis ReynoldsMajor ShareholderSell25,000$2.24$56,000.00View SEC Filing  
2/12/2014Francis ReynoldsMajor ShareholderSell37,500$2.25$84,375.00View SEC Filing  
2/7/2014Francis ReynoldsMajor ShareholderSell25,000$2.23$55,750.00View SEC Filing  
2/5/2014Francis ReynoldsMajor ShareholderSell37,500$2.21$82,875.00View SEC Filing  
1/31/2014Francis ReynoldsMajor ShareholderSell25,000$2.17$54,250.00View SEC Filing  
1/29/2014Francis ReynoldsMajor ShareholderSell37,500$2.22$83,250.00View SEC Filing  
1/24/2014Francis ReynoldsMajor ShareholderSell25,000$2.25$56,250.00View SEC Filing  
1/21/2014Francis ReynoldsMajor ShareholderSell37,500$2.36$88,500.00View SEC Filing  
1/15/2014Francis ReynoldsMajor ShareholderSell37,500$2.22$83,250.00View SEC Filing  
1/10/2014Francis ReynoldsMajor ShareholderSell48,000$2.41$115,680.00View SEC Filing  
1/6/2014Francis ReynoldsMajor ShareholderSell36,000$2.28$82,080.00View SEC Filing  
12/31/2013Francis ReynoldsMajor ShareholderSell36,000$2.25$81,000.00View SEC Filing  
12/26/2013Francis ReynoldsMajor ShareholderSell36,000$1.99$71,640.00View SEC Filing  
12/20/2013Francis ReynoldsMajor ShareholderSell24,000$1.96$47,040.00View SEC Filing  
12/18/2013Francis ReynoldsMajor ShareholderSell36,000$1.90$68,400.00View SEC Filing  
12/13/2013Francis ReynoldsMajor ShareholderSell24,000$1.80$43,200.00View SEC Filing  
12/11/2013Francis ReynoldsMajor ShareholderSell36,000$1.75$63,000.00View SEC Filing  
12/6/2013Francis ReynoldsMajor ShareholderSell24,000$1.59$38,160.00View SEC Filing  
12/4/2013Francis ReynoldsMajor ShareholderSell36,000$1.90$68,400.00View SEC Filing  
11/22/2013Francis ReynoldsMajor ShareholderSell24,000$1.92$46,080.00View SEC Filing  
11/20/2013Francis ReynoldsMajor ShareholderSell36,000$1.95$70,200.00View SEC Filing  
11/13/2013Francis ReynoldsMajor ShareholderSell36,000$1.14$41,040.00View SEC Filing  
11/8/2013Francis ReynoldsMajor ShareholderSell24,000$1.11$26,640.00View SEC Filing  
11/6/2013Francis ReynoldsMajor ShareholderSell36,000$1.16$41,760.00View SEC Filing  
11/1/2013Francis ReynoldsMajor ShareholderSell24,000$1.16$27,840.00View SEC Filing  
10/30/2013Francis ReynoldsMajor ShareholderSell36,000$1.23$44,280.00View SEC Filing  
10/25/2013Francis ReynoldsMajor ShareholderSell24,000$1.35$32,400.00View SEC Filing  
10/22/2013Francis ReynoldsMajor ShareholderSell24,000$1.40$33,600.00View SEC Filing  
10/18/2013Francis ReynoldsMajor ShareholderSell24,000$1.45$34,800.00View SEC Filing  
10/16/2013Francis ReynoldsMajor ShareholderSell36,000$1.49$53,640.00View SEC Filing  
10/11/2013Francis ReynoldsMajor ShareholderSell24,000$1.51$36,240.00View SEC Filing  
10/9/2013Francis ReynoldsMajor ShareholderSell36,000$1.41$50,760.00View SEC Filing  
10/4/2013Francis ReynoldsMajor ShareholderSell24,000$1.41$33,840.00View SEC Filing  
9/20/2013Francis ReynoldsMajor ShareholderSell24,000$1.37$32,880.00View SEC Filing  
9/18/2013Francis ReynoldsMajor ShareholderSell36,000$1.43$51,480.00View SEC Filing  
9/13/2013Francis ReynoldsMajor ShareholderSell24,000$1.50$36,000.00View SEC Filing  
9/11/2013Francis ReynoldsMajor ShareholderSell24,000$1.72$41,280.00View SEC Filing  
9/6/2013Francis ReynoldsMajor ShareholderSell24,000$1.61$38,640.00View SEC Filing  
9/4/2013Francis ReynoldsMajor ShareholderSell24,000$1.36$32,640.00View SEC Filing  
9/3/2013Sean F MoranCFOBuy20,000$1.02$20,400.00View SEC Filing  
8/30/2013Francis ReynoldsMajor ShareholderSell9,200$1.55$14,260.00View SEC Filing  
8/30/2013Sean F MoranCFOBuy40,000$1.30$52,000.00View SEC Filing  
8/28/2013Francis ReynoldsMajor ShareholderSell12,600$3.24$40,824.00View SEC Filing  
8/23/2013Francis ReynoldsMajor ShareholderSell21,300$4.07$86,691.00View SEC Filing  
8/21/2013Francis ReynoldsCEOSell36,000$4.12$148,320.00View SEC Filing  
8/16/2013Francis ReynoldsCEOSell24,000$4.24$101,760.00View SEC Filing  
8/14/2013Francis ReynoldsCEOSell36,000$4.34$156,240.00View SEC Filing  
8/9/2013Francis ReynoldsCEOSell24,000$4.42$106,080.00View SEC Filing  
8/7/2013Francis ReynoldsCEOSell36,000$4.46$160,560.00View SEC Filing  
8/2/2013Francis ReynoldsCEOSell24,000$4.57$109,680.00View SEC Filing  
7/30/2013Francis ReynoldsCEOSell24,000$5.11$122,640.00View SEC Filing  
7/26/2013Francis ReynoldsCEOSell24,000$5.29$126,960.00View SEC Filing  
7/24/2013Francis ReynoldsCEOSell36,000$5.72$205,920.00View SEC Filing  
7/19/2013Francis ReynoldsCEOSell24,000$5.27$126,480.00View SEC Filing  
7/17/2013Francis ReynoldsCEOSell36,000$5.12$184,320.00View SEC Filing  
7/12/2013Francis ReynoldsCEOSell24,000$4.43$106,320.00View SEC Filing  
7/10/2013Francis ReynoldsCEOSell36,000$3.97$142,920.00View SEC Filing  
7/5/2013Francis ReynoldsCEOSell12,000$4.00$48,000.00View SEC Filing  
7/3/2013Francis ReynoldsCEOSell36,000$4.08$146,880.00View SEC Filing  
6/28/2013Francis ReynoldsCEOSell24,000$4.22$101,280.00View SEC Filing  
6/26/2013Francis ReynoldsCEOSell36,000$3.87$139,320.00View SEC Filing  
6/21/2013Francis ReynoldsCEOSell24,000$3.78$90,720.00View SEC Filing  
6/19/2013Francis ReynoldsCEOSell36,000$3.89$140,040.00View SEC Filing  
6/14/2013Francis ReynoldsCEOSell24,000$3.84$92,160.00View SEC Filing  
6/12/2013Francis ReynoldsCEOSell12,750$4.34$55,335.00View SEC Filing  
6/7/2013Francis ReynoldsCEOSell8,500$4.02$34,170.00View SEC Filing  
6/5/2013Francis ReynoldsCEOSell12,750$3.75$47,812.50View SEC Filing  
6/5/2013Robert LangerMajor ShareholderSell7,500$3.73$27,975.00View SEC Filing  
5/31/2013Francis ReynoldsCEOSell8,500$3.32$28,220.00View SEC Filing  
5/31/2013Robert LangerMajor ShareholderSell7,500$3.31$24,825.00View SEC Filing  
5/29/2013Francis ReynoldsCEOSell8,500$3.13$26,605.00View SEC Filing  
5/28/2013Robert LangerMajor ShareholderSell7,500$2.97$22,275.00View SEC Filing  
5/24/2013Francis ReynoldsCEOSell8,500$2.95$25,075.00View SEC Filing  
5/22/2013Robert LangerMajor ShareholderSell7,500$2.88$21,600.00View SEC Filing  
5/21/2013Francis ReynoldsCEOSell12,750$2.88$36,720.00View SEC Filing  
5/17/2013Francis ReynoldsCEOSell8,500$2.87$24,395.00View SEC Filing  
5/17/2013Robert LangerMajor ShareholderSell7,500$2.85$21,375.00View SEC Filing  
5/15/2013Francis ReynoldsCEOSell12,750$2.89$36,847.50View SEC Filing  
5/14/2013Robert LangerMajor ShareholderSell7,500$2.91$21,825.00View SEC Filing  
5/10/2013Francis ReynoldsCEOSell8,500$2.92$24,820.00View SEC Filing  
5/9/2013Robert LangerMajor ShareholderSell7,500$2.91$21,825.00View SEC Filing  
4/12/2013Francis ReynoldsCEOSell8,500$3.16$26,860.00View SEC Filing  
2/5/2013Francis ReynoldsCEOSell12,750$2.03$25,882.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Latest Headlines for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Source:
DateHeadline
businesswire.com logoInVivo Therapeutics Announces Presentation at Combined Canadian Spinal Cord and Ontario Spinal Cord Injury ... - Business Wire (press release)
www.businesswire.com - May 11 at 9:16 AM
finance.yahoo.com logoInVivo Therapeutics Announces Presentation at Combined Canadian Spinal Cord and Ontario Spinal Cord Injury Research Network Meeting
finance.yahoo.com - May 9 at 11:26 AM
businesswire.com logoInVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study at Oregon Health and Science ... - Business Wire (press release)
www.businesswire.com - May 8 at 12:14 PM
finance.yahoo.com logoInVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study at Oregon Health and Science University
finance.yahoo.com - May 8 at 12:14 PM
americanbankingnews.com logoInvivo Therapeutics Holdings Corp (NVIV) Given Outperform Rating at Raymond James Financial, Inc.
www.americanbankingnews.com - May 5 at 10:36 AM
businesswire.com logoInVivo Therapeutics Provides Clinical Update and Reports 2017 ... - Business Wire (press release)
www.businesswire.com - May 5 at 9:03 AM
finance.yahoo.com logoInVivo Therapeutics Provides Clinical Update and Reports 2017 First Quarter Financial Results
finance.yahoo.com - May 4 at 7:05 PM
americanbankingnews.com logoInvivo Therapeutics Holdings Corp (NVIV) Getting Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - May 4 at 12:08 PM
americanbankingnews.com logoInvivo Therapeutics Holdings Corp (NVIV) Getting Somewhat Positive News Coverage, Report Shows
www.americanbankingnews.com - April 25 at 8:04 PM
americanbankingnews.com logoInvivo Therapeutics Holdings Corp (NVIV) Earning Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 22 at 3:52 PM
finance.yahoo.com logoInVivo Therapeutics Announces Oral Presentations at the 2017 American Spinal Injury Association Annual Scientific Meeting
finance.yahoo.com - April 20 at 9:17 AM
americanbankingnews.com logoInvivo Therapeutics Holdings Corp (NVIV) Getting Somewhat Positive Media Coverage, Study Finds
www.americanbankingnews.com - April 14 at 11:28 PM
businesswire.com logoInVivo Therapeutics Announces New Site for INSPIRE Study - Business Wire (press release)
www.businesswire.com - April 12 at 11:01 AM
finance.yahoo.com logoInVivo Therapeutics Announces New Patient Enrollment into the INSPIRE Study at the Carolinas Medical Center
finance.yahoo.com - April 7 at 11:36 AM
finance.yahoo.com logoInVivo Therapeutics Announces First Canadian Site for Cervical Spinal Cord Injury Study
finance.yahoo.com - March 30 at 7:14 PM
reuters.com logoBRIEF-Invivo Therapeutics appoints Christopher Mcnulty as CFO
www.reuters.com - March 29 at 9:25 AM
us.rd.yahoo.com logoInVivo Therapeutics Appoints Christopher McNulty as Chief Financial Officer
us.rd.yahoo.com - March 29 at 9:25 AM
reuters.com logoBRIEF-Invivo Therapeutics announces seventh patient conversion in study of neuro-spinal Scaffold
www.reuters.com - March 28 at 10:00 AM
finance.yahoo.com logoInVivo Therapeutics Announces Seventh Patient Conversion in The INSPIRE Study of the Neuro-Spinal Scaffold™
finance.yahoo.com - March 28 at 10:00 AM
finance.yahoo.com logoInVivo Therapeutics to Present at Needham and Company’s 16th Annual Healthcare Conference
finance.yahoo.com - March 27 at 10:02 AM
businesswire.com logoMarch 27 Deadline Alert: Law Offices of Howard G. Smith Reminds PixarBio Corporation Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm
www.businesswire.com - March 24 at 11:51 PM
streetinsider.com logoInvivo Therapeutics (NVIV) to Commence Clinical Study of Neuro-Spinal Scaffold - StreetInsider.com
www.streetinsider.com - March 24 at 6:51 PM
streetinsider.com logoInvivo Therapeutics (NVIV) to Commence Clinical Study of Neuro-Spinal Scaffold
www.streetinsider.com - March 23 at 7:26 PM
us.rd.yahoo.com logoInVivo to Initiate Cervical Spinal Cord Injury Study
us.rd.yahoo.com - March 23 at 7:26 PM
streetinsider.com logoInvivo Therapeutics (NVIV) Submits Nonclinical Studies Module for ... - StreetInsider.com
www.streetinsider.com - March 23 at 5:00 AM
reuters.com logoBRIEF-Invivo Therapeutics reports FDA submission
www.reuters.com - March 22 at 6:59 PM
streetinsider.com logoInvivo Therapeutics (NVIV) Submits Nonclinical Studies Module for Neuro-Spinal Scaffold to FDA
www.streetinsider.com - March 21 at 11:24 AM
finance.yahoo.com logoInVivo Therapeutics Announces Submission to the FDA of Its Nonclinical Studies Module for the Neuro-Spinal Scaffold™
finance.yahoo.com - March 21 at 11:24 AM
finance.yahoo.com logoInVivo Therapeutics Announces Enrollment of New Patient into the INSPIRE Study at New Jersey’s Cooper Neurological Institute
finance.yahoo.com - March 20 at 9:51 AM
businesswire.com logoInVivo Therapeutics Receives Clinical Trial Application Approval from UK's Medicines Healthcare Products Regulatory ... - Business Wire (press release)
www.businesswire.com - March 15 at 7:08 PM
reuters.com logoBRIEF-Invivo Therapeutics receives clinical trial application approval from UK's MHRA
www.reuters.com - March 15 at 9:46 AM
us.rd.yahoo.com logoInVivo Therapeutics Receives Clinical Trial Application Approval from UK's Medicines Healthcare Products Regulatory Agency
us.rd.yahoo.com - March 15 at 9:46 AM
us.rd.yahoo.com logo8:02 am InVivo Therapeutics: Medicines Healthcare Products Regulatory Agency has approved its Clinical Trial Authorization Application to commence clinical studies in the UK
us.rd.yahoo.com - March 15 at 9:46 AM
businesswire.com logoInVivo Therapeutics Reports 2016 Year-end Financial Results and Business Update - Business Wire (press release)
www.businesswire.com - March 11 at 11:44 PM
reuters.com logoBRIEF-Invivo Therapeutics qtrly adjusted net loss per diluted share 0.21
www.reuters.com - March 11 at 11:11 AM
marketwatch.com logo10-K: INVIVO THERAPEUTICS HOLDINGS CORP.
www.marketwatch.com - March 10 at 8:42 PM
biz.yahoo.com logoINVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 10 at 8:42 PM
us.rd.yahoo.com logoInVivo Therapeutics Reports 2016 Year-end Financial Results and Business Update
us.rd.yahoo.com - March 10 at 8:42 PM
finance.yahoo.com logoInVivo Therapeutics Announces Enrollment of New Patient into the INSPIRE Study at Keck Hospital, University of Southern California
finance.yahoo.com - March 9 at 8:15 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating InVivo Therapeutics Holdings Corp. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - March 8 at 7:43 PM
finance.yahoo.com logoPixarBio Lead Plaintiff Deadline Reminder: Hagens Berman Reminds Investors in PixarBio Corporation of …
finance.yahoo.com - March 6 at 6:24 PM
finance.yahoo.com logoBlock & Leviton Reminds PixarBio Corporation Investors Of ... - Yahoo Finance
finance.yahoo.com - March 4 at 8:44 AM
prnewswire.com logoBlock & Leviton Reminds PixarBio Corporation Investors Of Important Deadline In Securities Fraud Class Action
www.prnewswire.com - March 3 at 6:58 PM
finance.yahoo.com logoInVivo Therapeutics to Present and Exhibit at Spine Summit 2017
finance.yahoo.com - February 28 at 10:37 AM
finance.yahoo.com logoInVivo Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - February 27 at 5:46 PM
seekingalpha.com logoInVivo Therapeutics Holdings (NVIV) Presents at 19th Annual BIO CEO & Investor Conference
seekingalpha.com - February 14 at 10:08 PM
businesswire.com logoInVivo Therapeutics to Present at 2017 BIO CEO & Investor Conference - Business Wire (press release)
www.businesswire.com - February 7 at 4:29 PM
finance.yahoo.com logoInVivo Therapeutics to Present at 2017 BIO CEO & Investor Conference
finance.yahoo.com - February 7 at 9:16 AM
businesswire.com logoINVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of PixarBio Corporation Investors
www.businesswire.com - February 2 at 7:50 PM
prnewswire.com logoPixarBio Corporation Sued By Block & Leviton For Violations Of The Federal Securities Laws
www.prnewswire.com - January 31 at 5:42 AM

Social

Invivo Therapeutics Holdings Corp (NVIV) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff